Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

News

NIH Accelerates the Use of Genomics Sequencing in Clinical Care

Bethesda, MD, August 21, 2017 — The National Institutes of Health (NIH) on August 8 announced it is awarding $18.9 million towards research that aims to accelerate the use of genome sequencing in clinical care.

The new awards will generate innovative approaches and best practices to ensure that the effectiveness of genomic medicine can be applied to all individuals and groups, including diverse and underserved populations, and in healthcare settings that extend beyond academic medical centers. Continue reading

NJEDA to Make Additional Lab Space Available for State’s Growing Biotechnology Companies

Trenton, NJ, August 18, 2017 — The New Jersey Economic Development Authority (EDA) yesterday announced it will again expand its successful incubator program with the creation of the Biotechnology Development Center (BDC) on the 50-acre Technology Centre of New Jersey research park in North Brunswick.

The BDC will offer suites of intermediate lab and office space from 3,400 to 10,000 square feet for emerging life sciences companies including those that have outgrown incubator space and other early stage companies looking to expand. More than 32,600 square feet of new space is now available at the BDC. Continue reading

Rutgers Cancer Institute Reports Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer

Dr. Janice M. Mehnert

New Brunswick, NJ, August 18, 2017 — The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease.

That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).

Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses bak to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.” Continue reading

Stockton University Brain Research Team Seeking Volunteers in Atlantic City Area

Galloway, NJ, August 18, 2017 — Stockton University is seeking volunteers for a research project being conducted in Atlantic City, which will explore which lifestyle factors have the most significant impact on the degree of connectivity among different regions of the brain.

“As we age, we routinely participate in screenings of blood pressure, cholesterol and blood sugar,” noted Jessica Fleck, associate professor of Psychology.  “However, many individuals have never participated in a screening of brain health and function.” Continue reading

Christie Administration Announces $500,000 Grant Opportunity to Integrate Health Care for Military, Veterans and First Responders

Trenton, NJ, August 17, 2017 — The New Jersey Department of Health yesterday announced a $500,000 grant opportunity to support a pilot program to integrate primary care, behavioral health, palliative care, hospice and telehealth services for military persons, veterans and first responders.

This one-year grant opportunity is available to New Jersey hospitals, healthcare systems, federally qualified health centers, or state university providers of behavioral health services.

Military personnel, veterans and first responders often deal with primary care and behavioral health challenges. Offering the integration of healthcare across the continuum will help create a seamless system of care. Continue reading

Opinion: Assemblymen and Stevens President Urge ‘Restore Funding to Turbocharge NJ’s Research and Development’

Trenton, NJ, August 16, 2017Assemblyman Raj Mukherji (D-Hudson), Assemblyman Troy Singleton (D-Burlington) and Dr. Nariman Farvardin, president of Stevens Institute of Technology, write on innovation and Assembly No. 5123 in an op-ed published on August 15 in The Star-Ledger:

One need only to look at the top performers in the S&P 500 — Amazon, Apple, Google parent Alphabet and Facebook — to confirm an indisputable fact about our modern economy: Technological innovation is the key driver of economic growth.

Policymakers who ignore technology’s disruptive impact on markets, industries and jobs do so at their constituents’ peril. (Think Amazon’s impact on the retail industry.) Continue reading

Life Sciences Talent Network Shaping Future Leaders in NJ’s Biotech Industry

Trenton, NJ, August 16, 2017Matt Alcalde, Director of Life Sciences Talent Network at BioNJ, writes:

Now in its second year, the Life Sciences Talent Advisory Board, managed by the Life Sciences Talent Network at BioNJ, has engaged over 100 employers from New Jersey’s robust health and life sciences industry.

These employers include pharmaceutical, biotechnology and medical device companies that are researching and developing new drugs and therapies to treat various diseases affecting patients worldwide as well as others who are supporting that work. Continue reading

U.S. Senate’s ‘Right to Try’ Bill Could Face Slower Action in House

Washington, DC, August 15, 2017Roll Call reports that a U.S. Senate-passed “right to try” bill that is intended to help dying patients access experimental drugs, which have yet to receive Food and Drug Administration (FDA), likely will face lengthier deliberations in the U.S. House of Representatives.

While the Senate fast-tracked the bill on August 3, the House will likely subject it to a hearing and markup before bringing it up to a vote, according to congressional aides and a lobbyist.

The bill would reduce some of the paperwork involved in getting access to experimental treatments, and would offer protections to the drug companies who choose to make drugs available outside of a clinical trial. Continue reading

After 2-Year Hiatus, 2.3 Percent Medical Device Tax Could Be Reinstated on January 1; Industry Launches Campaign

Washington, DC, August 15, 2017 — Bob Salsberg reports in The Washington Post that the industry that makes medical devices from artificial hips to miniature pumps for IV drips is looking for a fallback plan to permanently repeal a widely reviled sales tax that almost met its end in Republicans’ health care legislation.

The 2.3 percent medical device excise tax — one of several taxes and fees in the Affordable Care Act that pay for expanded insurance coverage — has been the subject of ferocious lobbying by manufacturers seeking its permanent death.

Yet for now it’s on track to be reinstated on Jan. 1 after a two-year hiatus, leaving industry leaders worried it will hurt employment and stifle development of innovative, even lifesaving products. Continue reading

STAT: FDA Puts New Restrictions on Hiring of Foreign Scientists, Documents Show

Washington, DC, August 14, 2017 — Erin Mershon reports on STAT that the Food and Drug Administration (FDA) is implementing a new hiring protocol that could make it significantly harder for foreign scientists to find jobs and research opportunities at the agency, according to interviews and newly obtained documents.

Mershon reports that the FDA recently began directing hiring managers not to extend any employment offers — including for fellowship and contractor positions — to any individual who has not lived in the U.S. for at least three of the five previous years, according to briefing materials shared with STAT that have been presented to some agency employees. Continue reading